We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 2 of 5 for:    CF102

A Study of the Efficacy and Safety of CF102 in the Treatment of Non-Alcoholic Fatty Liver Disease

This study is not yet open for participant recruitment.
Verified October 2016 by Can-Fite BioPharma
Sponsor:
ClinicalTrials.gov Identifier:
NCT02927314
First Posted: October 7, 2016
Last Update Posted: October 7, 2016
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
Information provided by (Responsible Party):
Can-Fite BioPharma
  Purpose
This is a multicenter, randomized, double-blind, placebo-controlled clinical trial in subjects with NAFLD and NASH.

Condition Intervention Phase
Non-alcoholic Steatohepatitis (NASH) Drug: CF102 Drug: Placebo Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple (Participant, Care Provider, Investigator)
Primary Purpose: Treatment
Official Title: A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose-Finding Study of the Efficacy and Safety of CF102 in the Treatment of Non-Alcoholic Fatty Liver Disease (NAFLD) and Non-Alcoholic Steatohepatitis (NASH)

Resource links provided by NLM:


Further study details as provided by Can-Fite BioPharma:

Primary Outcome Measures:
  • Efficacy of CF102 in subjects with non-alcoholic fatty liver disease (NAFLD), as determined by the percent change from baseline in the liver triglyceride concentration measured by nuclear magnetic resonance spectroscopy (NMRS) [ Time Frame: 12 weeks ]
  • Nature, frequency, and severity (by CTCAE or comparable scale) of adverse events [ Time Frame: 12 weeks ]

Secondary Outcome Measures:
  • Change from baseline in body weight (kg) [ Time Frame: 12 weeks ]
  • Change from baseline in serum triglyceride and HDL cholesterol levels (mg/dL) [ Time Frame: 12 weeks ]
  • Change from baseline in serum liver transaminase levels (U/mL) [ Time Frame: 12 weeks ]
  • Change from baseline in Hb A1c levels (%) (in diabetic subjects only) [ Time Frame: 12 weeks ]
  • Change from baseline in: degree of insulin resistance by HOMA (IR units; in diabetic subjects only) [ Time Frame: 12 weeks ]
  • Trough serum concentrations of CF102 [ Time Frame: 12 weeks ]
  • Effect of CF102 on peripheral blood expression of the A3 adenosine receptor (A3AR) [ Time Frame: 12 weeks ]

Estimated Enrollment: 60
Study Start Date: February 2017
Estimated Primary Completion Date: February 2018 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Placebo Comparator: Placebo
Placebo tablets orally q12h
Drug: Placebo
orally q12h
Active Comparator: CF102 12.5mg
CF102 tablets orally q12h
Drug: CF102
orally q12h
Other Name: Cl-IB-MECA
Active Comparator: CF102 25mg
CF102 tablets orally q12h
Drug: CF102
orally q12h
Other Name: Cl-IB-MECA

Detailed Description:
This is a multicenter, randomized, double-blind, placebo-controlled study in subjects with a diagnosis of NAFLD. Subjects will undergo Screening procedures during the 4 weeks preceding Baseline. Subjects will be randomly assigned in a 1:1:1 ratio to oral doses of CF102 12.5 mg BID, CF102 25 mg BID, or matching placebo BID for 12 weeks using a stratified randomization, with stratification by presence or absence of diabetes mellitus. Subjects will be evaluated regularly for safety, and indicators of efficacy will be measured at Baseline and Week 12. Subjects will return for a follow-up visit 4 weeks after completion of the last dose of study drug.
  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. At least 18 years of age.
  2. Diagnosis of NAFLD by non-invasive determination of liver triglyceride concentration, as defined as triglyceride concentration ≥10.0% by NMRS.
  3. At least 2 of the following:

    • Obesity, defined as body mass index (BMI) of ≥25 and ≤40 kg/m2; or waist circumference >88 and <200 cm for women or >102 and <200 cm for men
    • Type II diabetes mellitus, defined by the criteria of the American Diabetes Association (Appendix 1)
    • Blood pressure of 130/85 or higher (either systolic or diastolic)
    • Hypertriglyceridemia, defined as >150 mg/dL (>1.7 mmol/L)
    • Reduced high-density lipoprotein (HDL) cholesterol, defined as <40 mg/dL (<1.04 mmol/L) in men or <50 mg/dL (<1.3 mmol/L) in women.
  4. Acceptable hepatic metabolic and synthetic function, as indicated at Screening by:

    • Serum albumin ≥3.5 gm/dL
    • INR ≤1.2
    • Serum total bilirubin ≤2.0 mg/dL.
  5. Absence of cirrhosis, defined as a Fibroscan score of ≤F4 and liver stiffness measurement (LSM) of 7 13 kPa.
  6. The following laboratory values must be documented at Screening prior to initiation of study drug:

    • Absolute neutrophil count >1.5x109/L
    • Platelet count >100x109/L
    • Serum creatinine <2.0 mg/dL.
  7. For women of childbearing potential, negative serum pregnancy test result (not pregnant or lactating).
  8. Understand and provide written informed consent to participate.
  9. Patients taking herbal supplements, homeopathic medications, or other alternative treatments, must be on a stable regimen for at least 6 months prior to randomization.
  10. Willing to comply with scheduled visits, treatment plans, laboratory assessments, and other study-related procedures.

Exclusion Criteria:

  1. Presence of ascites, hepatic encephalopathy, or other clinical evidence of cirrhosis.
  2. Other active acute or chronic liver disease, such as autoimmune hepatitis, hepatitis B, hepatitis C, alcoholic liver disease, or hepatocellular carcinoma at the time of Screening and randomization.
  3. Familial dyslipidemia.
  4. Weight loss of >5% within 6 months prior to Baseline.
  5. History of bariatric surgery within 5 years of Screening.
  6. Diabetes mellitus other than Type II.
  7. Daily alcohol intake >20 g/day for women and 30 g/day for men (on average per day), as per medical history.
  8. Treatment with the following anti-diabetic medications: DPP-4 inhibitor unless it was stopped 3 months before Screening, GLP-1 receptor agonists (such as Januvia [sitagliptin], Byetta [incretin], etc.) unless it was started at least 12 months and on stable dose at least 3 months prior to Screening.
  9. Metformin, fibrates, statins, insulin, or sulfonylurea unless the dose has been stabilized for the last 1 month prior to Screening.
  10. More than 7 days of treatment with valproic acid, tamoxifen, methotrexate, amiodarone, rifaximin, other antibiotics, or anti-cholinergic agents within 3 months prior to Screening.
  11. Uncontrolled or clinically unstable thyroid disease, in the judgment of the Principal Investigator.
  12. Seropositivity for markers of viral hepatitis or human immunodeficiency virus (HIV) at Screening.
  13. Uncontrolled arterial hypertension or congestive heart failure (New York Heart Association Classification 3 or 4).
  14. Angina, myocardial infarction, cerebrovascular accident, coronary/peripheral artery bypass graft surgery, transient ischemic attack, or pulmonary embolism within 3 months prior to initiation of study drug.
  15. History of or ongoing cardiac dysrhythmias requiring treatment, atrial fibrillation of any grade, or persistent prolongation of the QTc (Fridericia) interval to >450 msec for males or >470 msec for females.
  16. Pregnant or lactating female.
  17. Women of childbearing potential, unless they agree to use dual contraceptive methods which, in the opinion of the Principal Investigator, are effective and adequate for that patient's circumstances while on study drug.
  18. Men who partner with a woman of childbearing potential, unless they agree to use effective, dual contraceptive methods (ie, a condom, with female partner using oral, injectable, or barrier method) while on study drug.
  19. Any severe, acute, or chronic medical or psychiatric condition, or laboratory abnormality that may increase the risk associated with study participation or study drug administration, may interfere with the informed consent process and/or with compliance with the requirements of the study, or may interfere with the interpretation of study results and, in the investigator's opinion, would make the patient inappropriate for entry into this study.
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02927314


Contacts
Contact: Michael H Silverman, MD 972-3-9241114

Sponsors and Collaborators
Can-Fite BioPharma
Investigators
Study Director: Michael H Silverman, MD Can-Fite BioPharma Ltd
  More Information

Responsible Party: Can-Fite BioPharma
ClinicalTrials.gov Identifier: NCT02927314     History of Changes
Other Study ID Numbers: CF102-211LD
First Submitted: September 25, 2016
First Posted: October 7, 2016
Last Update Posted: October 7, 2016
Last Verified: October 2016

Additional relevant MeSH terms:
Liver Diseases
Fatty Liver
Non-alcoholic Fatty Liver Disease
Digestive System Diseases